Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
PLANO, Texas, March 01, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Management will also be available for one-on-one meetings at the conference.
Event: Cowen and Company 37th Annual Health Care Conference
Date: Wednesday, March 8, 2017
Time: 8:40 am ET
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
